Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:February 2012
End Date:January 2018

Use our guide to learn which trials are right for you!

Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by
lowering the amount of estrogen the body makes.

PURPOSE: This phase II trial is studying how well letrozole works in treating women with
ductal carcinoma in situ.

Treatment with letrozole begins within 21 days of registration, and only after notification
has been received from the UCSF Breast MRI Research Laboratory that the baseline MRI is
acceptable. Protocol therapy will consist of 6 months of letrozole, administered orally at a
dose of 2.5 mg/day. Patients will have a MRI for disease evaluation at months 3 and 6. All
patients will continue to take study drug until the day prior to surgery, whether at month 3
or at month 6 or may stop if they experience unacceptable toxicity. It is expected that
decisions regarding any adjuvant treatment (eg, radiation and hormonal therapy) will be made
individually based on the best practice guidelines, using informed and shared decision making
between patient and provider. The primary and secondary objectives are provided below.

Primary objective:

1. To estimate the mean change in MRI tumor volume from pretreatment to completion of
preoperative endocrine therapy in estrogen receptor-positive (ER+) ductal carcinoma in situ
(DCIS), as well as to determine whether 3-month change in volume correlates with 6-month
change.

Secondary objectives:

1. To assess radiographic-pathologic correlation between MRI findings and histopathology,
including the prevalence of occult invasive cancer in patients undergoing neoadjuvant
endocrine therapy for DCIS.

2. To compare changes in MRI maximum lesion diameter and mammographic extent at baseline
and following treatment. These are two additional radiographic parameters which may also
biological response to therapy.

3. To determine practice patterns of adjuvant hormonal and radiation therapy in patients
who complete neoadjuvant letrozole therapy for DCIS.

4. To determine whether Ki67 is reduced with neoadjuvant letrozole treatment for DCIS, and
to compare the reduction in proliferation between radiographic responders and
non-responders.

5. To identify baseline IHC and expression biomarkers predictive of response to treatment,
with response determined by extent of Ki67 reduction. Subsets showing the greatest
reduction in Ki67 would be the most likely candidates for non-operative treatment in
future studies.

6. To examine whether germline polymorphisms are associated with clinical endpoints,
including treatment-related toxicity or efficacy outcomes, or with expression of
biomarkers in serum or tumor.

7. To assess quality-of-life and musculoskeletal symptoms associated with neoadjuvant
letrozole for ER positive DCIS.

Patients will be followed up to 6 months post-surgery.

Eligibility Criteria:

1. Histologic documentation: Pathologic confirmation of ductal carcinoma in situ (DCIS)
of the female breast without invasive cancer, with diagnosis rendered on core biopsy
only, completed within 60 days before registration. Patients diagnosed with DCIS on
the basis of surgical biopsy are not eligible for this study.

1. Patients with microinvasion on diagnostic core biopsy, defined as tumor ≤ 1 mm in
greatest dimension, will be allowed to participate.

2. All patients must have a clip placed, either at the time of the diagnostic biopsy
or at the time of the baseline MRI prior to the start of treatment.

2. Tissue samples: Patient has diagnostic tissue available for correlative studies.

3. Clinical stage: Tis or T1mi N0, M0

4. Hormone receptor status: DCIS must express estrogen and/or progesterone receptor, as
determined by immunohistochemical methods on the diagnostic pathology sample,
according to the local institution's standard protocol. Greater than or equal to 1%
cells will be considered to be positive.

5. Menopausal status: Patients must be postmenopausal defined as:

1. Age ≥ 55 years and one year or more of amenorrhea

2. Age < 55 years and one year or more amenorrhea, with an estradiol assay < 20pg/ml

3. Surgical menopause with bilateral oophorectomy (at least 28 days must elapse from
surgery to time of study registration)

The use of GnRH analogs to achieve post menopausal status is not allowed.

6. Prior treatment:

1. No prior surgical excision in the index breast for current DCIS diagnosis of DCIS

2. Any exogenous hormone therapy must be completed 4 weeks prior to registration

3. Any patients with a history of tamoxifen or raloxifene use within two years of
current DCIS diagnosis are not eligible

4. No prior neoadjuvant/adjuvant therapy for current DCIS diagnosis

7. Contraindication to MRI: No contraindications to breast MRI

8. Measurable disease: Mammographic extent of calcifications must be accurately
measurable in at least one dimension with each lesion ≥ 1 cm and ≤ 7 cm

1. DCIS must be visible on MRI based on central review.

2. Patients with palpable DCIS or adenopathy are not eligible to participate.

3. Patients with multifocal or bilateral disease are eligible.

9. History of osteoporosis: Women diagnosed with osteoporosis may participate in this
trial provided they are receiving appropriate therapy or if they have declined
therapy.

10. Age: Patients ≥ 18 years of age

11. Performance Status: ECOG performance status 0 or 1

12. Pregnancy/nursing status: Not pregnant or nursing

13. Required Initial Laboratory Values:

1. ANC ≥ 1,000/μL

2. Platelet count ≥ 100,000/μL

3. Serum creatinine ≤ 1.7 mg/dL

4. Bilirubin ≤ 2.0 mg/dL

5. AST/ALT ≤ 2.5 times upper limit of normal

6. Serum estradiol level assay < 20 pg/mL *Required for patients < 55 years of age
and one year or more of amenorrhea
We found this trial at
32
sites
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Phone: 507-284-2166
Mayo Clinic Cancer Center The Mayo Clinic Cancer Center is a National Cancer Institute-designated comprehensive...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Phone: 919-966-5221
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Phone: 310-423-9331
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Phone: 617-632-2174
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Phone: 843-876-4420
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Columbus, Ohio 43210
Phone: 614-293-6654
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Phone: 614-488-2118
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
111 S Grant Ave
Columbus, Ohio 43215
(614) 566-9000
Phone: 614-488-2118
Grant Medical Center Founded in 1900 in Columbus' downtown, Grant has grown into one of...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1835 Franklin St
Denver, Colorado 80218
(303) 837-7111
Phone: 303-777-2663
Exempla Saint Joseph Hospital Founded in 1873 by the Sisters of Charity of Leavenworth, Saint...
?
mi
from
Denver, CO
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Phone: 919-681-9509
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Edgewood, Kentucky 41017
Phone: 859-301-9186
?
mi
from
Edgewood, KY
Click here to add this to my saved trials
Fort Thomas, Kentucky 41075
Phone: 859-301-9186
?
mi
from
Fort Thomas, KY
Click here to add this to my saved trials
Hampton, Virginia 23666
Phone: 757-594-1806
?
mi
from
Hampton, VA
Click here to add this to my saved trials
Hendersonville, North Carolina 28791
Phone: 828-692-8045
?
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-563-1872
?
mi
from
Houston, TX
Click here to add this to my saved trials
Iowa City, Iowa 52242
Phone: 319-356-2425
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
4401 Wornall Rd
Kansas City, Missouri 64111
(816) 932-2000
Phone: 913-948-5588
Saint Luke's Hospital, Kansas City Saint Luke's Hospital is a not-for-profit tertiary referral center committed...
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
1215 E Michigan Ave
Lansing, Michigan 48912
(517) 364-1000
Phone: 734-712-1000
Sparrow Hospital Sparrow has grown to become the region's largest health system, and its diverse...
?
mi
from
Lansing, MI
Click here to add this to my saved trials
Lexington, Kentucky 40503
Phone: 859-260-6295
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Newark, Delaware 19713
Phone: 302-366-1200
?
mi
from
Newark, DE
Click here to add this to my saved trials
Newark, Delaware 19713
Phone: 302-366-1200
?
mi
from
Newark, DE
Click here to add this to my saved trials
Newark, Delaware
Phone: 302-366-1200
?
mi
from
Newark, DE
Click here to add this to my saved trials
Newark, Delaware 19713
Phone: 302-366-1200
?
mi
from
Newark, DE
Click here to add this to my saved trials
4755 Ogletown-Stanton Road
Newark, Delaware 19718
302-733-1000
Phone: 302-366-1200
Christiana Care Health System - Christiana Hospital A 913-bed, 1.3-million-square-foot, modern facility in Newark, Delaware,...
?
mi
from
Newark, DE
Click here to add this to my saved trials
Norfolk, Virginia 23502
Phone: 757-594-1806
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Norfolk, Virginia 23507
Phone: 757-594-1806
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Oakland, California 94609
Phone: 510-428-3689
?
mi
from
Oakland, CA
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
1805 27th St
Portsmouth, Ohio 45662
(740) 356-5000
Phone: 614-488-2118
Southern Ohio Medical Center Southern Ohio Medical Center (SOMC) is a 222-bed 501(C)(3) not-for-profit hospital...
?
mi
from
Portsmouth, OH
Click here to add this to my saved trials
Randallstown, Maryland 21133
Phone: 410-701-4466
?
mi
from
Randallstown, MD
Click here to add this to my saved trials
3015 North Ballas Road
Saint Louis, Missouri 63131
(314) 996-5000
Phone: 217-876-6600
Missouri Baptist Medical Center You just feel it. The smile that greets you. The hand...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94115
Phone: 415-885-7691
?
mi
from
San Francisco, CA
Click here to add this to my saved trials